← Back to Home

How Long Can a Single Cell Therapy Treatment Last? Kyverna Reports One-Year Follow-Up Results in Stiff Person Syndrome

Walking improvements persisted for one year in 26 patients with stiff person syndrome after CAR-T therapy; another small study in myasthenia gravis also showed sustained benefits. These results offer clues about reducing long-term medication use, but more evidence is needed to establish durable remission.

By SURL BioNews

For patients with autoimmune diseases who depend on long-term immunotherapy, how long improvements from a single treatment last often matters more than the initial response. On September 24, Kyverna announced follow-up results for its cell therapy miv-cel: improvements in walking ability in patients with stiff person syndrome persisted for one year, while patients with generalized myasthenia gravis also showed signals of longer-term symptom improvement. However, both datasets came from small studies without control groups.

Miv-cel, formerly known as KYV-101, is a CD19-targeting CAR-T therapy made from patients’ own T cells and designed to eliminate B cells involved in autoimmune responses. Its development aims to achieve longer-lasting disease control through a single infusion; whether this can lead to sustained reductions in immunosuppressive treatment is the central question of this follow-up.

In the Phase 2 KYSA-8 trial in stiff person syndrome, all 26 adults had previously responded inadequately to at least one immunotherapy. This rare disease causes muscle stiffness and painful spasms that affect gait. According to results announced by the company and also reported by Cell & Gene Therapy Review, the median reduction from baseline in the time patients needed to complete a 25-foot walk test was 49% at month 12; among patients who achieved clinically meaningful improvement at the primary analysis, 95% maintained the benefit. This percentage refers to those who had already improved, rather than all participants.

Another Phase 2 study, KYSA-6, included only 7 patients with generalized myasthenia gravis. As of June 2026, 5 had been followed for at least one year, with the longest follow-up reaching approximately a year and a half; the other two had been followed for 9 months and 6 months, respectively. All 7 achieved clinically meaningful improvements in assessments of daily functioning and muscle strength at week 24; the 5 who had reached one year of follow-up also maintained improvements on the relevant scales.

At the last follow-up, 4 of the 7 patients, approximately 57%, maintained “minimal symptom expression,” defined as a score of 0 or 1 on the Myasthenia Gravis Activities of Daily Living scale. Medication findings must be understood according to the company’s definitions: at week 24, none were using the listed immunotherapies, including nonsteroidal immunosuppressants, steroids at doses exceeding 10 milligrams daily, and FcRn or complement inhibitors; at the last follow-up, 6 remained off immunosuppressants. These figures cannot be interpreted directly as meaning that all patients had stopped all medications.

Regarding safety, the company said neither study observed high-grade cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. However, the absence of specific serious events in a small number of participants cannot rule out rare or later-onset risks; the lack of a control group also limits interpretation of the magnitude and durability of efficacy. The findings released so far remain company summaries and cannot establish that the diseases have been cured.

These data will next face more direct scrutiny. Kyverna said it plans to include the one-year follow-up results in stiff person syndrome in a rolling Biologics License Application and complete the submission in the fourth quarter of 2026; the Phase 3 study in myasthenia gravis uses a randomized controlled design to compare miv-cel with standard treatment, with enrollment expected to be completed in mid-2027. Expectations for a one-time treatment will ultimately require more complete comparative data and longer follow-up to answer how long the benefits can last and what risks they entail.

References

  1. STAT
  2. Cell & Gene Therapy Review